Cover Image

Oncolytic parvoviruses as cancer therapeutics

The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular,...

Full description

Saved in:
Bibliographic Details
Main Authors: Rommelaere, Jean (Author) , Geletneky, Karsten (Author) , Angelova, Assia L. (Author) , Daeffler, Laurent (Author) , Dinsart, Christiane (Author) , Kiprianova, Irina (Author) , Schlehofer, Jörg R. (Author) , Raykov, Zahari Zahariev (Author)
Format: Article (Journal)
Language:English
Published: 7 March 2010
In: Cytokine & growth factor reviews
Year: 2010, Volume: 21, Issue: 2/3, Pages: 185-195
ISSN:1879-0305
DOI:10.1016/j.cytogfr.2010.02.011
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cytogfr.2010.02.011
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1359610110000225
Get full text
Author Notes:Jean Rommelaere, Karsten Geletneky, Assia L. Angelova, Laurent Daeffler, Christiane Dinsart, Irina Kiprianova, Joerg R. Schlehofer, Zahari Raykov
Description
Summary:The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
Item Description:Gesehen am 15.06.2023
Physical Description:Online Resource
ISSN:1879-0305
DOI:10.1016/j.cytogfr.2010.02.011

Similar Items